Beltran Pedro 4

What Happened

• Pedro Beltran, President, CEO and a director of BridgeBio Oncology Therapeutics, Inc. (BBOT), had 1,047 shares of the company's common stock withheld to satisfy tax withholding obligations related to vested restricted stock units (RSUs). The withholding was recorded at $7.80 per share for a total of $8,167. This is an administrative/withholding disposition (transaction code F), not an open-market sale.

Key Details

• Transaction date and price: July 1, 2026 — 1,047 shares withheld at $7.80 per share (total $8,167).
• Transaction type: Tax withholding on vested RSUs (code F; listed as “Disposed” because shares were withheld).
• Footnote: F1 — shares were withheld by the issuer to satisfy the reporting person’s tax withholding obligations on RSU vesting.
• Shares owned after transaction: Not specified in the provided filing extract.
• Filing: Report filed July 6, 2026; the filing shows the transaction and does not indicate a late filing.

Context

• This was a cashless tax withholding tied to RSU vesting (common practice) rather than a voluntary sale; such withholdings are routine and do not necessarily signal the insider’s view of the company’s prospects. Transaction code F denotes tax withholding rather than an open-market disposition.